Project Summary
Recent data from clinical trials with humanized or fully human mAbs targeting Aß suggest that immunotherapy
could clear/reduce brain amyloid plaques and even slow cognitive decline in vaccinated subjects when initiated
as a preventive measure. However, passive immunotherapy with even the most effective anti-Aß mAb is not
practical and cost-effective as a preventive measure in healthy subjects due to the need for frequent (monthly)
administrations of high concentrations (~800mg IV injections/each time) of this immunotherapeutic in a
substantial patient population. At the same time, high doses of mAb frequently (~30%) induce ARIA-E and ARIA-
H. In contrast, AD vaccine, similar to the vast majority of vaccines in general, could be very effective when used
as a preventive/early intervention measure. Today, only limited results are available from ACC001, CAD106,
and UB311 epitope vaccine clinical trials, but fortunately, comprehensive data on AN-1792 are published. These
data demonstrated that the AN-1792 vaccine has induced antibodies specific to N-terminus of amyloid in ~19%
immunized AD patients without causing ARIA-E and ARIA-H abnormalities. Importantly the follow-up analysis
revealed that even after 14 years post-vaccination, the vaccinated subjects were plaque-free, and there was a
significant inverse correlation between peripheral blood anti-Aß antibody titers and the plaque counts. Despite
the reduction of Aß pathology, vaccination did not improve cognitive functions likely due to tau pathology buildup.
These data support our long-standing proposal of starting anti-Aß vaccination with AV-1959D as a prophylactic
measure in subjects at risk for AD to inhibit/reduce oligomerization of Aß and delay downstream pathological
processes. However, based on an ethical imperative raised by the FDA during our pre-IND meeting, they
recommended us to test our Aß vaccine AV-1959D in participants with early-stage AD patients prior to initiating
the preventive trials in asymptomatic people at risk of MCI/AD. Therefore, here we propose to initiate a Phase 1
safety trial with the first-in-human Aß DNA vaccine, AV-1959D in early-stage MCI/AD patients based on FDA
cleared IND18953 developed under an NIA cooperative agreement (U01 AG048310). Importantly, our vaccine
strategy differs from all previous or current vaccines tested in clinical trials, as our approach is based on the very
immunogenic and proprietary MultiTEP platform designed for human use and aimed to (i) overcome self-
tolerance by inducing Th cell responses to MultiTEP, but not to self-Aß epitopes; (ii) diminish variability of immune
responses due to HLA diversity in humans; (iii) augment anti-Aß antibody production through activation of both
naïve and pre-existing memory Th cells, especially beneficial for elderly patients with immunosenescence.
Therefore, in Phase 1 trials, the first-in-human MultiTEP-based DNA vaccine targeting Aß1-11 B cell epitope
should be safe and should induce therapeutically sufficient titers of anti-Aß antibodies in an appreciable number
of vaccinated early stage AD subjects. Our future program includes preventive vaccine trial in asymptomatic
people at risk of MCI/AD using only the most immunogenic and safe dose of AV-1959D.
